Maravai LifeSciences Holdings, Inc. (MRVI)
MRVINASDAQ-GSBiotechnology: Pharmaceutical Preparations
$7.86
-0.1600 (-2.00%) today
At the close, Nov 10, 4:00 PM ET. After hours $8.01 +1.91%
- Market cap
- $2.04bn
- P/E
- –
- EPS, last 4 quarters
- $-0.2500
- Dividend yield
- –
- Day range
- $7.62 to $8.01
- 52-week range
- $2.80 to $9.42
- Average volume
- 2.56m
- Previous close
- $8.02
Analysts
5 coveringBuy3 buy, 2 hold, 0 sell
Targets a year out average $9.13, +16.2% from here
Earnings
next estimate $-0.0500Next report
Dec 2025
+22.2%
Mar 2026
+57.1%
Jun 2026
0.0%
Sep 2026
-14.3%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $49.87m | $65.84m | $51.44m | $45.85m |
| Gross profit | $12.84m | $33.70m | $20.65m | $16.19m |
| Operating income | -$58.80m | -$2.16m | -$15.09m | -$20.62m |
| Net income | -$35.68m | -$3.73m | -$12.42m | -$13.84m |
Last four quarters: revenue $213.00m, margin -30.8%, free cash flow -$13.27m
News
8 latest- Maravai LifeSciences Holdings Consensus Price Target Raised 11.76% to $9.69Fintel · 2 days ago
- Maravai LifeSciences (MRVI) Q3 2026 Earnings Call TranscriptThe Motley Fool · 5 days ago
- What Maravai LifeSciences (MRVI) Said on Its Q3 Earnings CallMarketBeat · 6 days ago
- Maravai LifeSciences Holdings, Inc. Reports Third Quarter 2026 Financial ResultsFintel · 6 days ago
- Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q3 Loss, Beats Revenue EstimatesZacks · 6 days ago
- Maravai LifeSciences Holdings Consensus Price Target Increased 11.84% to $8.67Fintel · Oct 23, 2026
- MRVI Crosses Above Average Analyst TargetBNK Invest · Sep 25, 2026
- Perrigo (PRGO) Moves 6.1% Higher: Will This Strength Last?Zacks · Sep 25, 2026
The company
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapies companies.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- maravai.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.